Zoom Debate lounge

Zoom Debate Lounge in Streams 1, 2 and 3

Dear Delegates
As an interactive addition to live streaming the CLINAM Foundation has installed a chat zoom room in each live stream. In each of the 3 rooms on Monday 26^th of October you have the possibility to join discussions (programme below)  On Tuesday and Wednesday you have the possibility to propose a topic to the community and organize a meeting yourself. The proposer acts as chair. Write us a mail with the topic and – when quality standard is approved – we will allocate you in a time slot.  The decision of the quality board cannot be discussed. The principle is on basis of first come first served. The slots are limited. Propose the topic to clinam@clinam.org and insert in the subject line “REQUEST FOR OWN SESSION”. Principally the sessions are 30 minutes of debate, however with further interest can last up to 1.5 hours. The Zoom Debate lounge will be daily updated with the chosen sessions. When you are in the Streaming Platform click at the debate-buttons at the bottom.

Programme Monday, 26.10.2020

Stream 1: 10.30–11.00

Prof. Dr. Dr. h.c. Viola Vogel, Head of the Laboratory of Applied Mechanobiology, ETH Zürich (CH)
New Nanotechnology Derived Insights and Approaches to Fight Infection and Inflammation
The purpose of this virtual discussion is to ask how nanotechnology tools could help to address major challenges in Medicine. This includes discussing how novel nanotech probes and imaging technologies are helping us to rewrite textbooks how pathogens invade hosts, and vice versa, how hosts are fighting infections, and equally important to define novel approaches to fight infection and inflammation more effectively, and hopefully one day with less side effects.

Stream 2: 11.00 –11.30

Prof. Dr. Janos Szebeni, professor of immunology and nanomedicine at Semmelweis U, also CEO/CSO of Seroscience Ltd, an immune toxicology CRO in Budapest (H)
Immune Side Effects of Nanomedicine
JS, will address questions on hypersensitivity reactions to and immunogenicity of nanoparticles. These adverse immune effects represent a risk for altered pharmacokinetics and/or life-threatening infusion reactions, which are potentially incompatible with the clinical use of nanomedicines and contrast agents. Over >20 years of experience in this field and the capability to serve the nanomedicine field with in vitro and in vivo assays predicting these adverse effects, Prof Szebeni is on the frontline in solving these problems.

Stream 3: 12.00 – 12.30

Prof. Dr. Rudolf Zentel, Institute of Organic Chemistry University of Mainz (D)
Nanoparticles in the Biological Context: Protein Corona Formation
Rudolf Zentel from the University of Mainz will elucidate: A recent paper demonstrated that the formation of a protein corona is not a general property of all types of nanosized objects. In fact, it varies between a massive aggregation of plasma proteins onto the nanoparticle down to traces (e.g. a few proteins per 10 nanoparticles), which can only be determined by mass spectrometry in comparison to appropriate negative controls. The difference is related to the surface morphology of the particles (the difference between a strongly hydrated / swollen shell vs a sharp “hard” surface). This topic is rarely discussed. Thus it should be considered that “not all nanoparticles are alike”!

Stream 1: 13.00 – 13.30

Dr. Dr. Josbert Metselaar, PharmD, PhD, Department of Experimental Molecular Imaging, RWTH Aachen, University Clinic, Aachen (D) and CEO Enceladus, Pharmaceuticals, Naarden (N)
Clinical and Commercial Feasibility of Nanomedicine Drug Product Development
Bart Metselaar (RWTH Aachen University) would like to open the floor of this debate lounge for a discussion about clinical and commercial feasibility of nanomedicine drug product development for inflammation. Inflammatory and autoimmune disease is a busy field to operate in with many new products ranging from small-molecular kinase inhibitors to monoclonal antibody biologics. How much room is there for new nanomedicine products? What inflammatory disease should we develop our products for? Should we answer this question from an unmet medical need point of view (top-down) or from a scientific rationale (bottom-up) point of view? All thoughts, comments and view are welcome, please share and join!

Stream 2: 14.00 – 14.30

Prof. Dr. med Patrick Hunziker, Leader of the Intensive Care Clinic of the University Hospital Basel, President of the International Society for Nanomedicine and CSO of the European Foundation for Clinical nanomedicine
Nanomedicine at Clinic
Patrick Hunziker has 12 years of experience in nanomedicine at the clinic. As a clinician he shows the hurdles and
the benefits of using nanotechnology in medicine. To what extent are today nanomedicines used and what are the future perspectves?

Further topics to be proposed by the delegates